Taysha Gene Therapies to Release Second Quarter 2025 Financial Results and Host Conference Call and Webcast on August 12
Rhea-AI Summary
Taysha Gene Therapies (NASDAQ:TSHA), a clinical-stage biotech company specializing in AAV-based gene therapies for CNS diseases, will host its Q2 2025 financial results conference call on August 12, 2025, at 8:30 AM ET. The company will present its financial performance for the quarter ended June 30, 2025, along with a corporate update.
Investors can access the call via toll-free number (877-407-0792) or international line (201-689-8263) using conference ID 13754869. A webcast will also be available on the company's investor relations website.
Positive
- None.
Negative
- None.
DALLAS, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that it will report its financial results for the second quarter ended June 30, 2025, and host a corporate update conference call and webcast on Tuesday, August 12, 2025, at 8:30 AM Eastern Time.
Conference Call Details
Tuesday, August 12, at 8:30 AM Eastern Time / 7:30 AM Central Time
Toll Free: 877-407-0792
International: 201-689-8263
Conference ID: 13754869
Webcast: https://ir.tayshagtx.com/news-events/events-presentations
About Taysha Gene Therapies
Taysha Gene Therapies (Nasdaq: TSHA) is a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system. Its lead clinical program TSHA-102 is in development for Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. With a singular focus on developing transformative medicines, Taysha aims to address severe unmet medical needs and dramatically improve the lives of patients and their caregivers. The Company’s management team has proven experience in gene therapy development and commercialization. Taysha leverages this experience, its manufacturing process and a clinically and commercially proven AAV9 capsid in an effort to rapidly translate treatments from bench to bedside. For more information, please visit http://www.tayshagtx.com.
Company Contact:
Hayleigh Collins
Senior Director, Corporate Communications and Investor Relations
Taysha Gene Therapies, Inc.
hcollins@tayshagtx.com
Media Contact:
Carolyn Hawley
Inizio Evoke
carolyn.hawley@inizioevoke.com
FAQ
When will Taysha Gene Therapies (TSHA) report Q2 2025 earnings?
How can investors access Taysha Gene Therapies' Q2 2025 earnings call?
What is Taysha Gene Therapies' main business focus?
What period will Taysha Gene Therapies' financial results cover?
